3.70
3.70 (0%)
As of Feb 14, 2025
Cargo Therapeutics, Inc [CRGX]
Source:
Company Overview
Cargo Therapeutics, Inc. is a clinical-stage biotechnology company focused on designing, engineering and developing next generation, potentially curative cell therapies for cancer patients. Our programs, platforms, and manufacturing strategy are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies.
| Country | United States |
| Headquarters | san mateo, california |
| Phone Number | (650) 379-6143 |
| Industry | manufacturing |
| CEO | Gina Chapman |
| Website | www.cargo-tx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-187.4 |
| Net Income | $-167.5 |
| Net Cash | $-341.4 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -38.6% |
| Profit as % of Stockholder Equity | -46.5% |
Management Effectiveness
| Return on Equity | -46.5% |
| Return on Assets | -40.5% |
| Turnover Ratio | |
| EBITA | $-187.4 |
Balance Sheet and Cash Flow Measures
| Total Assets | $414.1 |
| Total Liabilities | $53.8 |
| Operating Cash Flow | $-139.7 |
| Investing Cash Flow | $-305.1 |
| Financing Cash Flow | $103.5 |
